<p>Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic <em>BRCA2</em>-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review</p>-Reference-Cited by-同舟云学术

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review

Published:2020-12 Issue: Volume:Volume 13 Page:12979-12986
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Tao Mengyu,Cheng Jiejun,Wu Xia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference40 articles.

1. Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)

2. Brain Metastases in Patients with Ovarian Carcinoma: Prognostic Factors and Outcome

3. Brain metastasis from ovarian cancer: a systematic review

4. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature;Frontiers in Oncology;2024-08-02

2. Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: An institutional case series and literature review;Gynecologic Oncology Reports;2024-08

3. PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review;International Journal of Molecular Sciences;2024-07-18

4. Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China;Chinese Medical Journal;2024-04-26

5. Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer;Anticancer Research;2024-03-27